Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

Core Insights - Pfizer has agreed to acquire Metsera, a weight-loss drug developer, for up to $7.3 billion, marking its re-entry into the growing obesity drug market [1] Company Summary - The acquisition of Metsera allows Pfizer to expand its portfolio in the obesity treatment sector, which is experiencing significant growth [1] Industry Summary - The obesity drug market is burgeoning, indicating increasing demand and potential for new treatments [1]